Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Safety Study of USL261 in Outpatient Treatment of Seizure Clusters
2011-004109-25Phase 3Terminated
- Sponsor
- Upsher-Smith Laboratories
- Start
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ITI-111 in epilepsy and Cluster seizures (ARS), sponsored by Upsher-Smith Laboratories. Primary endpoint: Long-term safety and tolerability of USL261. Started Mar 2012; status: terminated.
02
Drugs
ITI-111
03
Conditions
epilepsyCluster seizures (ARS)
Beyond the preview
Go deeper on 2011-004109-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004109-25.